Nymox to present results of AlzheimAlert clinical studies at psychiatric meeting

By Lisa Kerner

Erie, Pa., May 1 - Nymox Pharmaceutical Corp. said it will present positive results from clinical studies of its AlzheimAlert test at the Annual Meeting of the American Psychiatric Association in Toronto.

The AlzheimAlert test, a urine-based diagnostic aid for Alzheimer's disease, is the only proven accurate non-invasive Alzheimer's test technology available, according to a company news release.

Nymox said the test has the CE Mark for marketing in Europe and is CLIA certified as a laboratory test service in the United States.

Alzheimer's disease affects an estimated 4.5 million people in the United States and is projected to affect about 13.2 million people by 2050, the release stated.

Located in Hasbrouck Heights, N.J., Nymox is a biopharmaceutical company specializing in therapeutics and diagnostics for the aging population.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.